^
Association details:
| Biomarker: | CX3CL1 underexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Excerpt:
...responses were associated with T-helper type 1 (TH1) gene expression, CTLA4 expression and the absence of fractalkine (CX3CL1) in baseline tumour specimens....Baseline CX3CL1 and CTLA4 gene expression levels are binned according to patient response to treatment with MPDL3280A.
DOI:
10.1038/nature14011
